Related Experiment Video
Updated: Dec 28, 2025
10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
26.4K
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention
Jessica Reid1,2, Khyatiben Rana1, Stephanie Niman1
1East Coast Institute for Research, 3550 University Blvd. South, Suite 101, Jacksonville, FL, 32216, USA.
Summary
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors show promise in reducing cardiovascular events for type 2 diabetes mellitus patients. These SGLT-2 inhibitors offer potential cardiovascular benefits, especially for those with existing heart conditions.
Area of Science:
- Endocrinology
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease (CVD) is a major cause of death in type 2 diabetes mellitus (T2DM) patients.
- Despite preventive therapies, residual risk for atherosclerotic CVD (ASCVD) remains high in T2DM.
- Managing T2DM and CVD, including heart failure (HF), is crucial for reducing adverse outcomes.
Purpose of the Study:
- To review the cardiovascular benefits of SGLT-2 inhibitors in T2DM patients.
- To evaluate the role of SGLT-2 inhibitors in preventing major adverse cardiovascular events (MACE).
- To assess the potential of SGLT-2 inhibitors as a CVD treatment option.
Main Methods:
- Review of recent clinical data and studies on SGLT-2 inhibitors.
- Analysis of cardiovascular outcomes associated with SGLT-2 inhibitor use in T2DM.
- Examination of data on MACE reduction in relevant patient populations.
Main Results:
- Antidiabetic medications, particularly SGLT-2 inhibitors, are associated with reduced MACE.
- SGLT-2 inhibitors demonstrate potential cardiovascular benefits in patients with CVD.
- Evidence suggests SGLT-2 inhibitors can help prevent CVD in diverse patient groups.
Conclusions:
- SGLT-2 inhibitors represent a significant advancement in managing cardiovascular risk in T2DM.
- These agents show potential value in preventing CVD and improving outcomes in patients with T2DM and existing cardiovascular conditions.
- Further research supports the role of SGLT-2 inhibitors in comprehensive cardiovascular risk management.
More Related Videos
08:32Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
10.7K
10:35Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
Published on: April 6, 2022
3.1K
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
535
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
535
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
472
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
472
01:06Oral Hypoglycemic Agents: Glinides
510
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
510
01:55Secondary Active Transport
136.2K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
136.2K
01:32Secondary Active Transport
9.1K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
9.1K
01:27Glucose Transporters
27.0K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.0K